Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
Sponsors and Collaborators
Robert Figlin, MD, FACP
Cedars-Sinai Medical Center
Christopher G Wood, MD, FACP
M.D. Anderson Cancer Center
Next post in Renal Cell Carcinoma Clinical Trials
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.